Table 1. Survivor Demographics and Treatment Characteristics.
| Characteristic | Value |
|---|---|
| Sex, No. (%) | |
| Male | 107 (50.5) |
| Female | 105 (49.5) |
| Age at evaluation, y | |
| Mean (SD) | 14.36 (4.79) |
| Median (range) | 13.23 (8.05-26.49) |
| Age at diagnosis, y | |
| Mean (SD) | 6.66 (4.54) |
| Median (range) | 5.04 (1.02-18.45) |
| Time since diagnosis, y | |
| Mean (SD) | 7.70 (1.70) |
| Median (range) | 7.52 (5.06-12.54) |
| Race/ethnicity, No. (%) | |
| Non-Hispanic white | 156 (73.58) |
| Other | 56 (26.42) |
| Highest education, y | |
| Mean (SD) | 7.50 (3.96) |
| Median (range) | 7.00 (2.00-17.00) |
| Highest parental education, y | |
| Mean (SD) | 14.58 (2.80) |
| Median (range) | 14.00 (6.00-22.00) |
| Treatment risk stratum, No (%)a | |
| Low | 121 (57.08) |
| Standard/high | 91 (42.92) |
| CNS involvement, No. (%) | |
| No blasts in CSF | 172 (81.13) |
| <5% blasts in CSF | 31 (14.62) |
| ≥5% blasts in CSF | 1 (0.47) |
| Traumatic LP with blasts | 8 (3.77) |
| High-dose IV methotrexate, g/m2 b | |
| Mean (SD) | 15.33 (5.00) |
| Median (range) | 14.30 (6.07-38.97) |
| TIT chemotherapy, mL | |
| Mean (SD) | 203.42 (85.84) |
| Median (range) | 190.48 (17.19-492.86) |
| TIT chemotherapy (No. of counts) | |
| Mean (SD) | 14.61 (4.05) |
| Median (range) | 13.00 (9.00-24.00) |
Abbreviations: CNS, central nervous system; CSF, cerebrospinal fluid; IV, intravenous; LP, lumbar puncture; TIT, triple intrathecal.
Criteria for low-risk acute lymphocytic leukemia (ALL): B-cell precursor ALL with DNA index 1.16 or greater, TEL-AML1 fusion, or age 1 to 9.9 years and white blood cell count of less than 50 × 109 cells per liter (to convert to cell count per microliter, multiply by 0.001). Must not have (1) CNS 3 status (≥5 white blood cells per liter of CSF with morphologically identifiable blasts or cranial nerve palsy), (2) overt testicular leukemia, (3) adverse genetic features (t(9;22) or BCR-ABL fusion, t(1;19) with E2A-PBX1 fusion, rearranged MLL, or hypodiploidy [<45 chromosomes]), or (4) poor early response (≥1% lymphoblasts on day 19 or 26 of remission induction, 0.01% or more lymphoblasts by immunologic or molecular methods on remission date). Criteria for standard-risk ALL: All cases of T-cell ALL and those of B-cell precursor ALL that do not meet the criteria for low-risk or high-risk ALL. Criteria for high-risk ALL: t(9;22) or BCR-ABL fusion; induction failure or more than 1% leukemic lymphoblasts in the bone marrow on remission date, more than 0.1% leukemic lymphoblasts in the bone marrow in week 7 of continuation treatment (ie, before reinduction, approximately 14 weeks post remission induction), re-emergence of leukemic lymphoblasts by minimal residual disease (MRD) (at any level) in patients previously MRD negative, and persistently detectable MRD at lower levels.
Cumulative doses are listed for IV methotrexate and TIT (methotrexate, hydrocortisone, and cytarabine). High-dose IV methotrexate was calculated separately. High-dose IV methotrexate was defined as daily dose of 1 gram per square meter of body surface area of IV methotrexate.